I2L Financial report 2019

Annual Report 2019

Inspire2Live is highly recognized in initiatives around personalized medicine, setting up innovative research for better treatments, concentration of cancer care in excellent cancer centres, better diagnosis, food and cancer, prevention (tobacco), the cost of drugs, the design of trials, influencing government and industry.

According to our chairman of the Supervisory Board, R. Stekelenburg, last year was a year of many changes for the better for patients. But still progress in general is too slow. There are two main forces that prohibit an increase in the speed of change:

  1. A lot of benefits can be achieved if patient data is shared among researchers, anonymously of course. Organizations are very cautious and most of the time too reluctant to participate in sharing information, inhibiting progress.
  2. Suggested changes are foremost assessed against the financial impact of that change instead of against the patient benefits of that change.

In general, we do see a change in mind-set in society showing the patient’s interest are becoming more important.

Inspire2Live as an organization becomes increasingly acknowledged for being an authority and a change agent in the field of cancer. Our organization now consists of 48 active Patient Advocates of which two in the USA, two in the UK, one in Switzerland, one in Austria, one in Spain and the remainder in The Netherlands.

We will keep on pushing to turn the tide and turn opposition into cooperation. Please find all information on our activities and financial report via the link below:

Inspire2Live Annual Report 2019

Should you have any further questions, please do not hesitate to contact us.

Peter Kapitein
CEO and Patient Advocate Inspire2Live